images

Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results

pharmafile | March 2, 2017 | News story | Research and Development Herceptin, Perjeta, Roche 

Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. The therapy improved invasive disease-free survival (iDFS) in those with HER2-positive early breast cancer (eBC) when administered post-surgery, compared to Herceptin and chemotherapy alone.

Sandra Horning, Chief Medical Officer and Head of Global Product Development at Roche, commented on the findings, saying: “These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer. We look forward to discussing these adjuvant results with global regulatory authorities.”

The combination therapy is already licensed as a pre-surgery solution for the disease in 75 countries, and the post-therapy treatment is currently under the FDA’s accelerated approval; Roche hopes this promising new data will aid the treatment’s path to full approval.

Gunter von Minckwitz, Study Coordinator from the Breast International Group and academic study partners, added: “APHINITY provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease.”

The aggressive HER2-positive breast cancer is known for poor prognoses and affects around 20% of breast cancer sufferers.

Matt Fellows

Related Content

Roche building

Roche’s Evrysdi drug for SMA shown to significantly increase survival

Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) …

Novartis signs capacity and technology transfer agreement for Roche drug

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology …

Roche building

Roche’s SMA treatment Evrysdi approved by European Commission

The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the …

Latest content